SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on April 3, 2003; DOI 10.1182/blood-2002-11-3567. This Article Full Text (PDF) All Versions of this Article: 2002-11-3567v1 102/3/820    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bornhauser, M. Articles by Anasetti, C. Search for Related Content PubMed PubMed Citation Articles by Bornhauser, M. Articles by Anasetti, C. Social Bookmarking                   What's this? Submitted November 26, 2002 Accepted March 29, 2003 Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells Martin Bornhauser*, Barry Storer, John T Slattery, Frederick R Appelbaum, H Joachim Deeg, John Hansen, Paul J Martin, George B Mc Donald, W Garrett Nichols, Jerald Radich, Ann Woolfrey, Andreas Jenke, Eberhard Schleyer, Christian Thiede, Gerhard Ehninger, and Claudio Anasetti Medizinische Klinik und Poliklinik I, University of Dresden, Dresden, Germany Fred Hutchinson Cancer Research Center, Seattle, WA, USA * Corresponding author; email: bornhaeuser{at}mk1.med.tu-dresden. A regimen of busulfan and cyclophosphamide is standard therapy before transplantation of allogeneic hematopoietic stem cells in patients with chronic myelogenous leukemia (CML) or myelodysplastic syndrome (MDS). The clinical trial reported here was undertaken to test the hypothesis that fludarabine can replace cyclophosphamide in this regimen and facilitate donor engraftment with reduced toxicity. The new conditioning regimen consisted of intravenous fludarabine 30 mg/m2 daily from day -9 to day -6, and oral busulfan given at 1 mg/kg x 16 every 6 h from day -5 to day -2, with doses adjusted to target plasma levels of 900±100 ng/ml at steady state. Cyclosporine and methotrexate were used for prophylaxis for graft-versus-host disease. Forty-two patients with high-risk CML (n=4) or MDS (n=38) were enrolled. The median patient age was 52 (range 12-65) years. Mobilized blood stem cells were obtained from HLA-compatible siblings (n=16) or unrelated donors (n=26). Engraftment was achieved in all patients, and the day-100 regimen-related mortality was 7%. With a median follow-up of 18 (range 13-27) months, the probabilities of overall survival, disease-free survival and non-relapse mortality were 42.4%, 34.9% and 24%, respectively. These data indicate that the combination of fludarabine and targeted busulfan is sufficiently immunosuppressive to facilitate engraftment of blood stem cells from HLA-matched siblings and unrelated donors. Based on these encouraging results, further studies of fludarabine and targeted busulfan are warranted in standard risk patients. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. H. Salinger, D. K. Blough, P. Vicini, C. Anasetti, P. V. O'Donnell, B. M. Sandmaier, and J. S. McCune A Limited Sampling Schedule to Estimate Individual Pharmacokinetic Parameters of Fludarabine in Hematopoietic Cell Transplant Patients Clin. Cancer Res., August 15, 2009; 15(16): 5280 - 5287. [Abstract] [Full Text] [PDF] H. J. Deeg Allogeneic Hematopoietic Cell Transplantation in Older Patients with Myelodysplastic Syndrome ASCO Educational Book, January 1, 2009; 2009(1): 420 - 424. [Abstract] [Full Text] [PDF] D-C Valla Budd-Chiari syndrome and veno-occlusive disease/sinusoidal obstruction syndrome Gut, October 1, 2008; 57(10): 1469 - 1478. [Full Text] [PDF] N. Kroger Epigenetic Modulation and Other Options to Improve Outcome of Stem Cell Transplantation in MDS Hematology, January 1, 2008; 2008(1): 60 - 67. [Abstract] [Full Text] [PDF] C. Chang, B. E. Storer, B. L. Scott, E. M. Bryant, H. M. Shulman, M. E. Flowers, B. M. Sandmaier, R. P. Witherspoon, R. A. Nash, J. E. Sanders, et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders Blood, August 15, 2007; 110(4): 1379 - 1387. [Abstract] [Full Text] [PDF] D. Blaise, N. Vey, C. Faucher, and M. Mohty Current status of reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia Haematologica, April 1, 2007; 92(4): 533 - 541. [Abstract] [Full Text] [PDF] E. A. Copelan Hematopoietic stem-cell transplantation. N. Engl. J. Med., April 27, 2006; 354(17): 1813 - 1826. [Full Text] [PDF] M. Stelljes, M. Bornhauser, M. Kroger, J. Beyer, M. C. Sauerland, A. Heinecke, B. Berning, C. Scheffold, G. Silling, T. Buchner, et al. Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia Blood, November 1, 2005; 106(9): 3314 - 3321. [Abstract] [Full Text] [PDF] M. de Lima, D. Couriel, P. F. Thall, X. Wang, T. Madden, R. Jones, E. J. Shpall, M. Shahjahan, B. Pierre, S. Giralt, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS Blood, August 1, 2004; 104(3): 857 - 864. [Abstract] [Full Text] [PDF] R. M. Stone, M. R. O'Donnell, and M. A. Sekeres Acute Myeloid Leukemia Hematology, January 1, 2004; 2004(1): 98 - 117. [Abstract] [Full Text] [PDF] J. R. Wingard, W. G. Nichols, and G. B. McDonald Supportive Care Hematology, January 1, 2004; 2004(1): 372 - 389. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020